数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

股本结构

单位:万股
公告日期 2020-08-10 2020-08-10 2020-05-11 2020-05-11 2020-03-27 2020-03-12
证券总股本 16752.04 15875.64 15809.65 14591.51 14579.01 14580.31
普通股本 16752.04 15875.64 15809.65 14591.51 14579.01 14580.31
优先股 未披露 未披露 未披露 未披露 未披露 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2020-08-07 2020-06-30 2020-05-08 2020-03-31 2020-03-17 2020-03-11
注释:中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本(万股) 变动后优先股(万股) 变动原因 变动日期
2020-08-10 16752.04 未披露 定期报告 2020-08-07
2020-08-10 15875.64 未披露
更多>>
From March 31, 2020 to June 30, 2020 Conversion of preferred stock to common stock Exercise of stock options for cash and vesting of RSUs, net of tax payments Issuance of common stock for cash
2020-06-30
2020-05-11 15809.65 未披露 定期报告 2020-05-08
2020-05-11 14591.51 未披露
更多>>
From December 31, 2019 to March 31, 2020 Issuance of common stock for cash Exercise of stock options for cash and vesting of RSUs, net of tax payments
2020-03-31
2020-03-27 14579.01 未披露 定期报告 2020-03-17
2020-03-12 14580.31 未披露 定期报告 2020-03-11
2020-03-09 13776.99 未披露 定期报告 2020-02-29
2020-03-12 10136.10 0.0023
更多>>
from December 31, 2018 to December 31, 2019 Issuance of common stock for cash Exercise of stock options for cash and vesting of RSUs, net of tax payments
2019-12-31
2019-11-12 10001.03 未披露 定期报告 2019-11-07
2019-11-12 9904.62 0.0023
更多>>
from June 30, 2019 to September 30, 2019 Issuance of common stock for cash Vesting of RSUs
2019-09-30
2019-08-08 9902.78 未披露 定期报告 2019-08-05
2019-08-08 9858.44 0.0023
更多>>
from March 31, 2019 to June 30,2019 Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments
2019-06-30
2019-05-09 9803.38 未披露 定期报告 2019-05-06
2019-05-09 9793.40 0.0023
更多>>
from December 31, 2018 to March 31, 2019 Issuance of common stock for cash Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments
2019-03-31
2019-03-25 9793.40 未披露 定期报告 2019-03-25
2019-03-25 9762.77 0.0023 定期报告 2019-03-11
2019-03-12 9763.64 未披露 定期报告 2019-03-08
2019-03-12 9722.58 0.0023
更多>>
from December 31, 2017 to December 31, 2018 Issuance of common stock for cash Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments
2018-12-31
2018-11-08 9534.71 未披露 定期报告 2018-11-02
2018-11-08 9447.24 0.0023 定期报告 2018-09-30
2018-08-07 9149.68 未披露 定期报告 2018-08-03
2018-08-07 9147.44 0.0023 定期报告 2018-06-30
2018-05-09 9096.21 未披露 定期报告 2018-05-04
2018-05-09 9070.49 0.0023 定期报告 2018-03-31
2018-03-28 9070.08 0.0023 定期报告 2018-03-16
2018-03-14 9040.39 未披露 定期报告 2018-03-08
2018-03-14 9035.76 0.0023
更多>>
from December 31, 2016 to December 31, 2017 Issuance of common stock for cash, net of financing costs of $4.9 million Exercise of stock options for cash and vesting of RSUs, net of tax payments
2017-12-31
2017-11-08 9029.62 未披露 定期报告 2017-11-03
2017-11-08 9029.49 0.0023 定期报告 2017-09-30
2017-08-08 9022.72 未披露 定期报告 2017-08-04
2017-08-08 7763.38 0.0023 定期报告 2017-06-30
2017-05-10 7462.70 0.0023 定期报告 2017-03-31
2017-03-29 7432.41 0.0023 定期报告 2017-03-17
2017-03-15 7410.14 未披露 定期报告 2017-03-08
2017-03-15 7406.24 0.0023
更多>>
From December 31, 2015 to December 31, 2016 Issuance of common stock for cash, net of financing costs of $128,000 Issuance of common stock for Bioject acquisition Exercise of stock options and warrants for cash, net of tax payments Cashless exercise of stock options and warrants
2016-12-31
2016-11-09 7406.05 未披露 定期报告 2016-11-01
2016-11-09 7396.67 0.0023 定期报告 2016-09-30
2016-08-08 7354.83 未披露 定期报告 2016-08-01
2016-08-08 7348.29 0.0023 定期报告 2016-06-30
2016-05-09 7309.71 未披露 定期报告 2016-05-02
2016-05-09 7226.82 0.0023 定期报告 2016-03-31
2016-03-25 7222.40 0.0023 定期报告 2016-03-18
2016-03-14 7222.40 未披露 定期报告 2016-03-07
2016-03-14 7221.80 0.0023
更多>>
from December 31, 2014 to December 31, 2015 Issuance of common stock for cash, net of financing costs of $4.0 million Exercise of stock options and warrants for cash
2015-12-31
2015-11-09 7218.32 未披露 定期报告 2015-11-02
2015-11-09 7218.08 0.0023 定期报告 2015-09-30
2015-08-10 7211.68 未披露 定期报告 2015-08-03
2015-05-22 7181.02 0.0023 定期报告 2015-05-20
2015-05-11 7181.00 未披露 定期报告 2015-05-05
2015-03-16 6074.11 0.0023
更多>>
from December 31, 2013 to December 31, 2014 Issuance of shares related to reverse stock split Issuance of common stock for cash, net of financing costs of $4.0 million Conversions of preferred stock to common stock Exercise of stock options and warrants for cash Cashless exercise of warrants
2014-12-31
2014-11-10 6059.11 未披露 定期报告 2014-11-03
2014-11-10 6045.79 0.0023 定期报告 2014-09-30
2014-08-11 6039.90 未披露 定期报告 2014-08-04
2014-08-11 6031.77 0.0023
更多>>
On June 5, 2014, we effectuated a 4-for-1 reverse split of the Company's outstanding common stock
2014-06-30
2014-05-12 24062.98 未披露 定期报告 2014-05-02
2014-04-07 24014.63 0.0026 定期报告 2014-03-24
2014-03-17 23960.98 未披露 定期报告 2014-03-07
2014-01-31 21140.50 0.0026 定期报告 2014-01-29
2014-03-17 21030.48 0.0026
更多>>
from December 31, 2012 to December 31, 2013 Issuance of common stock and warrants for cash, net of financing costs of $783,000 Issuance of common stock for cash, net of financing costs of $585,000 Exercise of stock options and warrants for cash Cashless exercise of warrants
2013-12-31
2013-11-12 20837.65 未披露 定期报告 2013-11-04
2013-11-12 20762.00 0.0026 定期报告 2013-09-30
2013-08-09 18990.34 未披露 定期报告 2013-08-08
2013-08-09 18005.86 0.0026 定期报告 2013-06-30
2013-03-29 17994.09 0.0026 定期报告 2013-03-25
2013-03-18 17992.12 未披露 定期报告 2013-03-08
2013-03-18 14431.30 0.0026
更多>>
from December 31, 2011 to December 31, 2012 Issuance of common stock for cash, net of financing costs of $164,695
2012-12-31
2012-11-07 13936.38 未披露 定期报告 2012-11-02
2012-11-07 13705.54 0.0026 定期报告 2012-09-30
2012-03-15 13496.84 0.0026
更多>>
from December 31, 2010 to December 31, 2011 Issuance of common stock for cash, net of financing costs of $41,838 Issuance of common stock and warrants for cash, net of financing costs of $1.3 million Issuance of common stock and warrants for cash, net of financing costs of $314,871 Exercise of stock options and warrants for cash
2011-12-31
2011-11-07 12726.87 未披露 定期报告 2011-10-26
2011-11-07 12725.69 0.0026 定期报告 2011-09-30
2011-05-10 12725.69 未披露 定期报告 2011-05-03
2011-05-10 12725.40 0.0026 定期报告 2011-03-31
2011-03-16 12725.40 未披露 定期报告 2011-02-24
2011-03-16 10503.82 0.0026
更多>>
from December 31, 2009 to December 31, 2010 Issuance of common stock for cash, net of financing costs of $71,839 Exercise of stock options for cash
2010-12-31
2010-11-12 10420.84 未披露 定期报告 2010-11-10
2010-11-12 10346.65 0.0026 定期报告 2010-09-30
2010-08-13 10288.99 0.0026 定期报告 2010-06-30
2010-03-26 10276.57 未披露 定期报告 2010-03-04
2010-03-26 10274.61 0.0026
更多>>
from December 31,2008 to December 31,2009 Issuance of common stock to VGX Pharmaceutical Shareholders Issuance of common stock and warrants for cash, net of financing costs of $1.6 million Exercise of stock options for cash Cashless exercise of stock options Conversions of preferred stock to common stock Conversion of convertible debt to common stock Stock-based compensation
2009-12-31
2009-03-31 4404.18 未披露 定期报告 2009-03-16
2009-03-31 4402.31 0.0071
更多>>
from December 31,2007 to December 31,2008 Exercise of stock options for cash Conversions of preferred stock to common stock Issuance of common stock for consulting services Stock-based compensation
2008-12-31
2008-03-17 4384.47 未披露 定期报告 2008-03-07
2008-03-17 4381.47 11.34
更多>>
from December 31,2006 to December 31,2007 Exercise of warrants for cash Exercise of stock options for cash Cashless exercise of warrants Conversions of preferred stock to common stock Conversions of ordinary shares to common stock Issuance of common stock for consulting services Issuance of common stock for cash, net of issuance costs of $110,313 Share-based compensation
2007-12-31
2007-03-16 3817.62 未披露 定期报告 2007-03-08
2007-03-16 3563.95 102.81
更多>>
from December 31,2005 to December 31,2006 Conversions of preferred stock to common stock Exercise of stock options for cash Issuance of common stock for patents and other assets Issuance of common stock for cash, net of issuance costs of $1,161,070 Issuance of common stock for consulting service Share-based compensation Imputed and declared dividends
2006-12-31
2006-03-16 2969.97 未披露 定期报告 2006-03-09
2006-03-16 2946.88 156.24
更多>>
from December 31,2004 to December 31,2005 Exercise of stock options for cash Exercise of warrants for cash Cashless exercise of warrants Issuance of common stock for cash, net of issuance costs of $997,682 Issuance of Series D preferred stock for acquisition of Inovio AS Conversions of preferred stock to common stock Imputed and declared dividends Upon conversion, the Series C Preferred Stock outstanding as of December 31, 2005 would convert into 495,769 shares of our common stock. Upon conversion, the Series A and B Preferred Stock would convert into a total of 573,808 shares of our common stock.
2005-12-31
2005-03-15 2001.29 未披露 定期报告 2005-03-02
2005-03-15 1842.04 0.14
更多>>
from December 31,2003 to December 31,2004 Exercise of stock options for cash Exercise of warrants for cash Cashless exercise of warrants Conversions of preferred stock to common stock Declared dividends Issuance of Series C preferred stock for cash, net of issuance costs of$1,170,363 Reversal of declared dividends Effective September 13, 2004, we implemented a one-for-four reverse split of our common stock.
2004-12-31
2004-03-30 6931.29 未披露 定期报告 2004-03-12
2004-03-30 6368.17 0.08
更多>>
from December 31,2002 to December 31,2003 Issuance of preferred stock net of issuance cost of $1,058,864 for cash Issuance of common stock for corporate finance services Exercise of stock options for cash Exercise of warrants for cash Conversions of preferred stock to common Declared dividends
2003-12-31
2003-03-31 5042.36 未披露 定期报告 2003-03-14
2003-03-31 5039.86 未披露
更多>>
from December 31,2001 to December 31,2002 Exercise of stock options for cash Exercise of warrants for cash Issued pursuant to exercise of special warrants (net of issuance costs of $413,833 incurred in 2002) Issued pursuant to exercise of series A special warrants Issued pursuant to exercise of special warrants Common stock issued pursuant to services In October 2002, these special warrants were converted into 10,225,891 shares of common stock and 3,557,976 common stock purchaser warrants.
2002-12-31
2002-04-01 3486.02 未披露 定期报告 2002-03-20
2002-04-01 3376.10 未披露
更多>>
from MARCH 31,2001 to December 31,2001 Exercise of stock options for cash
2001-12-31
2001-05-18 3375.67 未披露
更多>>
from MARCH 31,2000 to MARCH 31,2001 For cash Pursuant to private placement Pursuant to exercise of stock options Pursuant to exercise of warrants Issued for corporate finance services Issued pursuant to exercise of Special Warrants Issued pursuant to license agreement
2001-03-31
2000-06-28 2726.42 未披露 定期报告 2000-06-20
2000-06-28 2283.23 未披露
更多>>
from MARCH 31, 1999 to MARCH 31,2000 For cash Pursuant to exercise of stock options Pursuant to exercise of Agent's Special Warrants Issued for corporate finance services Issued pursuant to exercise of Special Warrants Cancelled escrow shares
2000-03-31
1999-06-29 2166.63 未披露
更多>>
from MARCH 31, 1998 to MARCH 31, 1999 For cash Pursuant to private placement Pursuant to exercise of stock options Pursuant to exercise of warrants
1999-03-31
From March 31, 2020 to June 30, 2020 Conversion of preferred stock to common stock Exercise of stock options for cash and vesting of RSUs, net of tax payments Issuance of common stock for cash
From December 31, 2019 to March 31, 2020 Issuance of common stock for cash Exercise of stock options for cash and vesting of RSUs, net of tax payments
from December 31, 2018 to December 31, 2019 Issuance of common stock for cash Exercise of stock options for cash and vesting of RSUs, net of tax payments
from June 30, 2019 to September 30, 2019 Issuance of common stock for cash Vesting of RSUs
from March 31, 2019 to June 30,2019 Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments
from December 31, 2018 to March 31, 2019 Issuance of common stock for cash Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments
from December 31, 2017 to December 31, 2018 Issuance of common stock for cash Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments
from December 31, 2016 to December 31, 2017 Issuance of common stock for cash, net of financing costs of $4.9 million Exercise of stock options for cash and vesting of RSUs, net of tax payments
From December 31, 2015 to December 31, 2016 Issuance of common stock for cash, net of financing costs of $128,000 Issuance of common stock for Bioject acquisition Exercise of stock options and warrants for cash, net of tax payments Cashless exercise of stock options and warrants
from December 31, 2014 to December 31, 2015 Issuance of common stock for cash, net of financing costs of $4.0 million Exercise of stock options and warrants for cash
from December 31, 2013 to December 31, 2014 Issuance of shares related to reverse stock split Issuance of common stock for cash, net of financing costs of $4.0 million Conversions of preferred stock to common stock Exercise of stock options and warrants for cash Cashless exercise of warrants
On June 5, 2014, we effectuated a 4-for-1 reverse split of the Company's outstanding common stock
from December 31, 2012 to December 31, 2013 Issuance of common stock and warrants for cash, net of financing costs of $783,000 Issuance of common stock for cash, net of financing costs of $585,000 Exercise of stock options and warrants for cash Cashless exercise of warrants
from December 31, 2011 to December 31, 2012 Issuance of common stock for cash, net of financing costs of $164,695
from December 31, 2010 to December 31, 2011 Issuance of common stock for cash, net of financing costs of $41,838 Issuance of common stock and warrants for cash, net of financing costs of $1.3 million Issuance of common stock and warrants for cash, net of financing costs of $314,871 Exercise of stock options and warrants for cash
from December 31, 2009 to December 31, 2010 Issuance of common stock for cash, net of financing costs of $71,839 Exercise of stock options for cash
from December 31,2008 to December 31,2009 Issuance of common stock to VGX Pharmaceutical Shareholders Issuance of common stock and warrants for cash, net of financing costs of $1.6 million Exercise of stock options for cash Cashless exercise of stock options Conversions of preferred stock to common stock Conversion of convertible debt to common stock Stock-based compensation
from December 31,2007 to December 31,2008 Exercise of stock options for cash Conversions of preferred stock to common stock Issuance of common stock for consulting services Stock-based compensation
from December 31,2006 to December 31,2007 Exercise of warrants for cash Exercise of stock options for cash Cashless exercise of warrants Conversions of preferred stock to common stock Conversions of ordinary shares to common stock Issuance of common stock for consulting services Issuance of common stock for cash, net of issuance costs of $110,313 Share-based compensation
from December 31,2005 to December 31,2006 Conversions of preferred stock to common stock Exercise of stock options for cash Issuance of common stock for patents and other assets Issuance of common stock for cash, net of issuance costs of $1,161,070 Issuance of common stock for consulting service Share-based compensation Imputed and declared dividends
from December 31,2004 to December 31,2005 Exercise of stock options for cash Exercise of warrants for cash Cashless exercise of warrants Issuance of common stock for cash, net of issuance costs of $997,682 Issuance of Series D preferred stock for acquisition of Inovio AS Conversions of preferred stock to common stock Imputed and declared dividends Upon conversion, the Series C Preferred Stock outstanding as of December 31, 2005 would convert into 495,769 shares of our common stock. Upon conversion, the Series A and B Preferred Stock would convert into a total of 573,808 shares of our common stock.
from December 31,2003 to December 31,2004 Exercise of stock options for cash Exercise of warrants for cash Cashless exercise of warrants Conversions of preferred stock to common stock Declared dividends Issuance of Series C preferred stock for cash, net of issuance costs of$1,170,363 Reversal of declared dividends Effective September 13, 2004, we implemented a one-for-four reverse split of our common stock.
from December 31,2002 to December 31,2003 Issuance of preferred stock net of issuance cost of $1,058,864 for cash Issuance of common stock for corporate finance services Exercise of stock options for cash Exercise of warrants for cash Conversions of preferred stock to common Declared dividends
from December 31,2001 to December 31,2002 Exercise of stock options for cash Exercise of warrants for cash Issued pursuant to exercise of special warrants (net of issuance costs of $413,833 incurred in 2002) Issued pursuant to exercise of series A special warrants Issued pursuant to exercise of special warrants Common stock issued pursuant to services In October 2002, these special warrants were converted into 10,225,891 shares of common stock and 3,557,976 common stock purchaser warrants.
from MARCH 31,2001 to December 31,2001 Exercise of stock options for cash
from MARCH 31,2000 to MARCH 31,2001 For cash Pursuant to private placement Pursuant to exercise of stock options Pursuant to exercise of warrants Issued for corporate finance services Issued pursuant to exercise of Special Warrants Issued pursuant to license agreement
from MARCH 31, 1999 to MARCH 31,2000 For cash Pursuant to exercise of stock options Pursuant to exercise of Agent's Special Warrants Issued for corporate finance services Issued pursuant to exercise of Special Warrants Cancelled escrow shares
from MARCH 31, 1998 to MARCH 31, 1999 For cash Pursuant to private placement Pursuant to exercise of stock options Pursuant to exercise of warrants